Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 305, Issue 1, 2013, Pages

  Mishra, Shikha ^a   Guan, Jian ^a   Plovie, Eva ^a   Seldin, David C ^b   Connors, Lawreen H ^b   Merlini, Giampaolo ^c   Falk, Rodney H ^a   MacRae, Calum A ^a   Liao, Ronglih ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amyloidosis; Apoptosis; In vivo model cardiovascular disease; P38 mitogen activated protein kinase

Indexed keywords

AMYLOID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CELL DEATH; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; HEART AMYLOIDOSIS; HEART DISEASE; HEART EDEMA; HEART MUSCLE NECROSIS; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; IN VIVO STUDY; LIGHT CHAIN; MOLECULAR DYNAMICS; MORTALITY; MULTIPLE MYELOMA; NONHUMAN; PERICARDIUM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL; ZEBRA FISH;

AMYLOIDOSIS; APOPTOSIS; IN VIVO MODEL CARDIOVASCULAR DISEASE; P38 MITOGEN-ACTIVATED PROTEIN KINASE;

AMYLOID; AMYLOIDOSIS; ANIMALS; APOPTOSIS; CARDIOMYOPATHIES; CARDIOTOXINS; DEATH; DISEASE MODELS, ANIMAL; HEART; HUMANS; MAP KINASE SIGNALING SYSTEM; MYOCARDIUM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; ZEBRAFISH;

EID: 84879576449     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00186.2013     Document Type: Article

References (33)

1. Ali S, Champagne DL, Spaink HP, Richardson MK. Zebrafish embryos and larvae: a new generation of disease models and drug screens. Birth Defects Res C Embryo Today 93: 115-133, 2011.
2. Bagatto B, Burggren W. A three-dimensional functional assessment of heart and vessel development in the larva of the zebrafish (Danio rerio). Physiol Biochem Zool 79: 194-201, 2006.
3. Bakkers J. Zebrafish as a model to study cardiac development and human cardiac disease. Cardiovasc Res 91: 279-288, 2011.
4. Bradford Y, Conlin T, Dunn N, Fashena D, Frazer K, Howe DG, Knight J, Mani P, Martin R, Moxon SA, Paddock H, Pich C, Ramachandran S, Ruef BJ, Ruzicka L, Bauer Schaper H, Schaper K, Shao X, Singer A, Sprague J, Sprunger B, Van Slyke C, Westerfield M. ZFIN: enhancements and updates to the Zebrafish Model Organism Database. Nucleic Acids Res 39: D822-829, 2011.
5. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, Liao R. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 94: 1008-1010, 2004.
6. Chico TJ, Ingham PW, Crossman DC. Modeling cardiovascular disease in the zebrafish. Trends Cardiovasc Med 18: 150-155, 2008.
7. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107: 3378-3383, 2006.
8. Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91: 141-157, 1998.
9. Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78: 74-82, 1997.
10. Etchin J, Kanki JP, Look AT. Zebrafish as a model for the study of human cancer. Methods Cell Biol 105: 309-337, 2011.
11. Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 124: 1079-1085, 2011.
12. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 112: 2047-2060, 2005.
13. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86: 180-186, 2011.
14. Guan J, Mishra S, Falk RH, Liao R. Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol 302: H544-H552, 2012.
15. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. Stages of embryonic development of the zebrafish. Dev Dyn 203: 253-310, 1995.
16. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107: 2446-2452, 2003.
17. Kumar SK, Gertz MA, Lacy MQ, Dingli D, Hayman SR, Buadi FK, Short-Detweiler K, Zeldenrust SR, Leung N, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Dispenzieri A. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 86: 12-18, 2011.
18. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 122: 78-84, 2003.
19. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, Falk RH, Apstein CS. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 104: 1594-1597, 2001.
20. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 29: 1924-1933, 2011.
21. Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, Phillips SA. Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol 145: 67-68, 2010.
22. Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, Timmons M, Motta A, Phillips SA, Hari P. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol 301: H2305-H2312, 2011.
23. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, D'Eril GM, Fogari R, Moratti R, Merlini G. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107: 3854-3858, 2006.
24. 2 channel. Nature 466: 874-878, 2010.
25. Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, Marwick TH, Thomas JD. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98: 1442-1448, 2012.
26. Sager JJ, Bai Q, Burton EA. Transgenic zebrafish models of neurodegenerative diseases. Brain Struct Funct 214: 285-302, 2010.
27. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA 107: 4188-4193, 2010.
28. Shin JT, Pomerantsev EV, Mably JD, MacRae CA. High-resolution cardiovascular function confirms functional orthology of myocardial contractility pathways in zebrafish. Physiol Genomics 42: 300-309, 2010.
29. Shin JT, Ward JE, Collins PA, Dai M, Semigran HL, Semigran MJ, Seldin DC. Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report. Amyloid 19: 191-196, 2012.
30. Sikkink LA, Ramirez-Alvarado M. Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell Death Dis 1: e98, 2010.
31. van Ham TJ, Mapes J, Kokel D, Peterson RT. Live imaging of apoptotic cells in zebrafish. FASEB J 24: 4336-4342, 2010.
32. Westerfield M. The Zebrafish Book: a Guide for the Laboratory Use of Zebrafish (Danio rerio). Eugene, OR: Univ. of Oregon Press, 2000.
33. Zon LI. Zebrafish: a new model for human disease. Genome Res 9: 99-100, 1999.